Study drug for nerve tumor caused by PRC2 loss
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 trial studies ASTX727 in people with malignant peripheral nerve sheath tumors (MPNST) that have a specific genetic change (“PRC2 loss”). It aims to shrink or control advanced tumors that have not responded to at least one standard treatment, by testing how well the drug works and is tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your MPNST must be confirmed in lab testing to have PRC2 loss (or certain related gene changes).
- Your tumor must be advanced and not removable by surgery, such as metastatic or unresectable cancer.
- You must be at least 16 years old and able to take pills by mouth.
- Your overall health should be fairly strong (ECOG 0 to 2).
- Your scans must show measurable disease that can be tracked by the trial’s imaging rules.
- Your blood and organ tests (kidney, liver, blood counts) must meet specific ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
This study tests whether a new drug called BMS-986504 is safe and effective for treating malignant peripheral nerve sheath tumors (MPNST) that cannot be surgically removed. The drug targets a specific genetic change (MTAP deletion) found in these tumors.
This Phase 1 study tests how well Lutathera combined with ASTX727 can treat neuroendocrine tumors. It looks mainly at whether the combination can be given safely and effectively for people whose tumors have grown or not tolerated standard first treatment.
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
Hear when a new Malignant Peripheral Nerve Sheath Tumors (MPNST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.